Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$11.08+0.18 (+1.65%)
Close on Nov 18, 2026Market cap $2.42BP/E –Yield –
Neogen pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Neogen's pe ratio was 263.0× on Mar 28, 2024, against 31.0× a year earlier. Over the last 5 years it ranged from 31.0× to 543.8×, with a median of 64.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Mar 28, 2024 | 263.0× | −280.8 |
| 2023 | Jun 30, 2023 | 543.8× | +499.0 |
| 2022 | Dec 30, 2022 | 44.8× | −33.5 |
| 2021 | Dec 31, 2021 | 78.3× | +7.5 |
| 2020 | Dec 31, 2020 | 70.8× | +13.6 |
| 2019 | Dec 31, 2019 | 57.2× | +12.4 |
| 2018 | Dec 31, 2018 | 44.9× | −24.4 |
| 2017 | Dec 29, 2017 | 69.3× | −19.9 |
| 2016 | Dec 30, 2016 | 89.2× | +6.4 |
| 2015 | Dec 31, 2015 | 82.8× | −0.9 |
| 2014 | Dec 31, 2014 | 83.7× | +4.6 |
| 2013 | Dec 31, 2013 | 79.1× | +17.2 |
| 2012 | Dec 31, 2012 | 62.0× | +19.9 |
| 2011 | Dec 30, 2011 | 42.1× | −29.9 |
| 2010 | Dec 31, 2010 | 72.0× | – |
See a number that looks wrong?